A Phase 3 interventional study of Pembrolizumab and Pemetrexed in Carcinoma, Nonsquamous Non-small-cell Lung, sponsored by Merck Sharp & Dohme LLC. Completed at 178 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 402 studies in Carcinoma with a site in United States — 70 open to participants now, 112 under way, 19 of them phase 3. Carcinoma · United States.
Among the 402 studies in Carcinoma with a site in United States, this one is the 6th largest by enrollment of the 358 interventional ones that give a count, is one of 21 that started in 2019, is one of 49 in phase 3, and was the 261st registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →70 of the 402 studies in Carcinoma with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120 · Men only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Pfizer · Sites in United States
Ages 18+
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
402 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 161 · Phase 2 171 · Phase 3 53 · Phase 4 7
First in 1996; this study’s year is marked. 21 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,003 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 48 across the 358 interventional studies, 108 across the 40 observational. Of the 267 that completed or were terminated, 121 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
210 of 402 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 8 studies filed under Carcinoma — fewer than ten, so there is no comparison to draw.
35 of the studies in Carcinoma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT05050162Phase 3NRG OncologyComparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer | 2027-02-09 |
| NCT06693336ToLymph Inc.An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer | 2026-11-18 |
| NCT04520711Providence Health & ServicesHotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) | 2026-12 |
| NCT05768932SillaJen, Inc.BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | 2026-12-24 |
Add all 35 to your calendar (.ics) → With an account.
Among the 402 studies in Carcinoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).
This study has 2 phases: an Induction Phase of up to \~4 Cycles (up to \~12 weeks [cycle =3 weeks]) and a Maintenance Phase of up to \~31 cycles of pembrolizumab (cycle = 3 weeks]); total pembrolizumab treatment duration will be up to \~35 cycles (up to \~2 years). In the Induction Phase, participants receive pembrolizumab plus pemetrexed plus platinum (carboplatin or cisplatin, at the investigator's discretion). In the Maintenance Phase, participants with a partial or complete disease response or with stable disease after completing four cycles of induction therapy and who meet eligibility criteria will be randomly assigned to receive pembrolizumab plus maintenance olaparib OR pembrolizumab plus maintenance pemetrexed. In the Maintenance Phase, participants receive pembrolizumab for up to 31 cycles (cycle = 3 weeks) plus maintenance olaparib OR maintenance pemetrexed until progressive disease (PD), intolerable toxicities, or physician decision.
Qualified participants in each study arm of the maintenance phase (Pembrolizumab plus Olaparib and Pembrolizumab plus Pemetrexed) who complete up to \~35 cycles of pembrolizumab (up to \~2 years [cycle =3 weeks]) may be eligible to receive a second course of pembrolizumab for up to \~17 cycles (up to \~1 additional year). Per protocol, response or progression during the second pembrolizumab course will not be counted towards patient reported outcomes (PROs) or efficacy outcome measures and adverse events during the second pembrolizumab course will not be counted towards safety outcome measures.
The criteria were revised on the registry on Sep 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have provided sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.
Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For the Induction Phase, participants receive 4 cycles (up to \~12 weeks \[cycle = 3 weeks\]): pembrolizumab 200 mg intravenous (IV) on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m\^2 IV on Day 1 of each cycle (Cycles 1 through 4). If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. The participant can continue to receive maintenance olaparib until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to \~35 cycles (up to \~2 years \[cycle = 3 weeks\]).
Biological: Pembrolizumab · Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin · Drug: Olaparib
For the Induction Phase, participants receive 4 cycles (up to \~12 weeks \[cycle = 3 weeks\]): pembrolizumab 200 mg IV on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m\^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin AUC 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m\^2 IV on Day 1 of each cycle (Cycles 1 through 4). If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance pemetrexed 500 mg/m\^2 IV on Day 1 of each 3-week cycle. The participant can continue to receive maintenance pemetrexed until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to \~35 cycles (up to \~2 years \[cycle = 3 weeks\]).
Biological: Pembrolizumab · Drug: Pemetrexed · Drug: Carboplatin · Drug: Cisplatin
IV infusion
Also known as: MK-3475, KEYTRUDA®
IV infusion
Also known as: ALIMTA®
IV infusion
Also known as: PARAPLATIN®
IV infusion
Also known as: PLATINOL®, PLATINOL®-AQ
Oral Tablet
Also known as: LYNPARZA®
Progression-free Survival (PFS)
PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was analyzed by the non-parametric Kaplan-Meier (K-M) method. The protocol specified final analysis of PFS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Up to ~31 months
Overall Survival (OS)
OS was defined as the time from randomization to death due to any cause. OS was analyzed by the non-parametric K-M method. Participants without documented death at the time of analyses were censored at the date of last known to be alive. The protocol specified final analysis of OS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Up to ~51 months
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.
Time frame: Up to ~5 years
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.
Time frame: Up to ~5 years
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Baseline and Week 24
Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome was not done in the Induction Phase.
Time frame: Up to ~24 months
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 cough (Item 1) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Baseline and Week 24
TTD in EORTC QLQ-LC13 Cough (Item 1) Scale Score
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 1). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Up to ~24 months
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 chest pain (Item 10) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Baseline and Week 24
TTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in chest pain (Item 10). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Up to ~24 months
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Baseline and Week 24
TTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Up to ~24 months
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Baseline and Week 24
TTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
Time frame: Up to ~24 months
| Milestone | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|---|
| Started | 1003 | 0 | 0 |
| Completed | 672 | 0 | 0 |
| Not completed | 331 | 0 | 0 |
| Withdrew: Failure to meet maintenance randomization criteria | 251 | 0 | 0 |
| Withdrew: Death | 80 | 0 | 0 |
| Milestone | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|---|
| Started | 0 | 337 | 335 |
| Treated | 0 | 337 | 332 |
| Received second course of pembrolizumab | 0 | 7 | 13 |
| Completed | 0 | 0 | 0 |
| Not completed | 0 | 337 | 335 |
| Withdrew: Participant ongoing in study | 0 | 100 | 97 |
| Withdrew: Withdrawal by subject | 0 | 9 | 3 |
| Withdrew: Physician decision | 0 | 0 | 1 |
| Withdrew: Death | 0 | 228 | 234 |
PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was analyzed by the non-parametric Kaplan-Meier (K-M) method. The protocol specified final analysis of PFS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Months | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| Progression-free Survival (PFS) | 7.1 (5.6 to 8.7) | 8.3 (6.9 to 11.5) |
OS was defined as the time from randomization to death due to any cause. OS was analyzed by the non-parametric K-M method. Participants without documented death at the time of analyses were censored at the date of last known to be alive. The protocol specified final analysis of OS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Months | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| Overall Survival (OS) | 20.7 (18.0 to 24.8) | 23.0 (19.0 to 26.4) |
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.
Results for this outcome have not been posted.
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course.
Results for this outcome have not been posted.
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Scores on a scale | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score | -5.34 (-7.78 to -2.90) | -3.44 (-5.90 to -0.98) |
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome was not done in the Induction Phase.
| Months | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score | 19.81 (15.97 to NA) | 17.28 (9.46 to NA) |
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 cough (Item 1) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Scores on a scale | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score | -1.98 (-4.90 to 0.94) | -1.82 (-4.77 to 1.12) |
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 1). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Months | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| TTD in EORTC QLQ-LC13 Cough (Item 1) Scale Score | NA (NA to NA) | NA (NA to NA) |
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 chest pain (Item 10) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Scores on a scale | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score | -0.82 (-3.25 to 1.61) | -0.47 (-2.92 to 1.98) |
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in chest pain (Item 10). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Months | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| TTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score | NA (NA to NA) | NA (NA to NA) |
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Scores on a scale | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score | -0.16 (-3.07 to 2.76) | 1.35 (-1.60 to 4.31) |
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Months | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| TTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score | NA (NA to NA) | NA (NA to NA) |
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Scores on a scale | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score | -2.79 (-4.92 to -0.65) | -2.78 (-4.93 to -0.62) |
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase.
| Months | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) |
|---|---|---|
| TTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score | 20.96 (13.34 to NA) | NA (17.28 to NA) |
Collected over Up to ~51 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | 116/1,003 (11.6%) | 235/1,003 (23.4%) | 872/1,003 (86.9%) |
| Pembrolizumab (First Course) + Olaparib (Maintenance Phase) | 233/337 (69.1%) | 118/337 (35%) | 298/337 (88.4%) |
| Pembrolizumab (First Course) + Pemetrexed (Maintenance Phase) | 233/335 (69.6%) | 125/332 (37.7%) | 289/332 (87%) |
| Pembrolizumab (Second Course) + Olaparib (Maintenance Phase) | 0/7 (0%) | 0/7 (0%) | 2/7 (28.6%) |
| Pembrolizumab (Second Course) + Pemetrexed (Maintenance Phase) | 2/13 (15.4%) | 1/13 (7.7%) | 9/13 (69.2%) |
| Event | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab (First Course) + Olaparib (Maintenance Phase) | Pembrolizumab (First Course) + Pemetrexed (Maintenance Phase) | Pembrolizumab (Second Course) + Olaparib (Maintenance Phase) | Pembrolizumab (Second Course) + Pemetrexed (Maintenance Phase) |
|---|---|---|---|---|---|
| Respiratory tract infectionInfections and infestations | 1/1003 | 1/337 | 0/332 | 0/7 | 1/13 |
| COVID-19 pneumoniaInfections and infestations | 9/1003 | 6/337 | 17/332 | 0/7 | 0/13 |
| PneumoniaInfections and infestations | 23/1003 | 14/337 | 11/332 | 0/7 | 0/13 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 7/1003 | 7/337 | 10/332 | 0/7 | 0/13 |
| AnaemiaBlood and lymphatic system disorders | 24/1003 | 9/337 | 8/332 | 0/7 | 0/13 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 10/1003 | 7/337 | 0/332 | 0/7 | 0/13 |
| ThrombocytopeniaBlood and lymphatic system disorders | 18/1003 | 0/337 | 2/332 | 0/7 | 0/13 |
| COVID-19Infections and infestations | 2/1003 | 6/337 | 2/332 | 0/7 | 0/13 |
| DeathGeneral disorders | 8/1003 | 3/337 | 5/332 | 0/7 | 0/13 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/1003 | 3/337 | 5/332 | 0/7 | 0/13 |
| Event | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab (First Course) + Olaparib (Maintenance Phase) | Pembrolizumab (First Course) + Pemetrexed (Maintenance Phase) | Pembrolizumab (Second Course) + Olaparib (Maintenance Phase) | Pembrolizumab (Second Course) + Pemetrexed (Maintenance Phase) |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 385/1003 | 122/337 | 125/332 | 1/7 | 2/13 |
| NauseaGastrointestinal disorders | 310/1003 | 81/337 | 63/332 | 0/7 | 0/13 |
| NeutropeniaBlood and lymphatic system disorders | 235/1003 | 57/337 | 32/332 | 0/7 | 0/13 |
| FatigueGeneral disorders | 140/1003 | 58/337 | 54/332 | 0/7 | 0/13 |
| ThrombocytopeniaBlood and lymphatic system disorders | 114/1003 | 57/337 | 35/332 | 0/7 | 0/13 |
| ConstipationGastrointestinal disorders | 169/1003 | 21/337 | 39/332 | 0/7 | 0/13 |
| Aspartate aminotransferase increasedInvestigations | 81/1003 | 28/337 | 55/332 | 0/7 | 0/13 |
| Alanine aminotransferase increasedInvestigations | 110/1003 | 31/337 | 52/332 | 0/7 | 0/13 |
| Decreased appetiteMetabolism and nutrition disorders | 155/1003 | 52/337 | 52/332 | 0/7 | 1/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 36/1003 | 33/337 | 38/332 | 0/7 | 2/13 |
Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase): All participants allocated to the pembrolizumab + Pemetrexed + Platinum Therapy arm in the Induction phase but not randomized into the maintenance phase; Pembrolizumab + Olaparib (Maintenance Phase): All participants randomized to the Pembrolizumab + Olaparib arm post Induction Phase; Pembrolizumab + Pemetrexed (Maintenance Phase): All participants randomized to the Pembrolizumab + Pemetrexed arm post Induction Phase.
| Age, Continuous(Years) | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) | Total |
|---|---|---|---|---|
| Mean | 63.3 ± 9.4 | 61.6 ± 8.6 | 61.8 ± 9.8 | 62.3 ± 9.3 |
| Sex: Female, Male(Participants) | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) | Total |
|---|---|---|---|---|
| Female | 109 | 110 | 109 | 328 |
| Male | 222 | 227 | 226 | 675 |
| Ethnicity (NIH/OMB)(Participants) | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 59 | 50 | 67 | 176 |
| Not Hispanic or Latino | 246 | 263 | 253 | 762 |
| Unknown or Not Reported | 26 | 24 | 15 | 65 |
| Race (NIH/OMB)(Participants) | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 4 | 1 | 10 |
| Asian | 56 | 91 | 72 | 219 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 | 4 |
| Black or African American | 9 | 4 | 8 | 21 |
| White | 236 | 218 | 234 | 688 |
| More than one race | 11 | 7 | 9 | 27 |
| Unknown or Not Reported | 14 | 11 | 9 | 34 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at Baseline of Maintenance Phase(Participants) | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) | Total |
|---|---|---|---|---|
| Grade 0 | 0 | 142 | 135 | 277 |
| Grade 1 | 0 | 195 | 200 | 395 |
| Response at Baseline of Maintenance Phase(Participants) | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) | Total |
|---|---|---|---|---|
| Complete Response (CR)/Partial Response (PR) | 0 | 189 | 192 | 381 |
| Stable Disease (SD) | 0 | 148 | 143 | 291 |
| Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline of Maintenance Phase(Participants) | Pembrolizumab + Pemetrexed + Platinum Therapy (Induction Phase) | Pembrolizumab + Olaparib (Maintenance Phase) | Pembrolizumab + Pemetrexed (Maintenance Phase) | Total |
|---|---|---|---|---|
| TPS<50% | 0 | 228 | 223 | 451 |
| TPS ≥50% | 0 | 109 | 110 | 219 |
| Not Evaluable | 0 | 0 | 1 | 1 |
| Missing | 0 | 0 | 1 | 1 |
Showing the first 100 of 178 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jun 2019 to primary completion in Feb 2024, 55 months.
Results were first posted in Feb 2025, 11 months after primary completion.
Of 35 phase 3 interventional studies under Carcinoma, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 82. This study's 55 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib